Citations

Clear

371 citation(s) found for "Cho, B".

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Bowtell, David D.L., Cramer, Daniel W., DeFazio, Anna , Doherty, Jennifer A. , Fereday, Sian, Fortner, Renée T. , Goode, Ellen L., Goodman, Marc T., Menon, Usha , Moysich, Kirsten B., Qin, Bo , Ramus, Susan J. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Trabert, Britton , Wentzensen, Nicolas, Wu, Anna H., Khoja, Lilah , Richardson, Jean , Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Odunsi, Kunle , Brenton, James D. , Terry, Kathryn L., Pharoah, Paul D.P., Berchuck, Andrew, Hanley, Gillian E., Pike, Malcolm C. , Pearce, Celeste Leigh, Goodman, Marc T. , Terry, Kathryn L. , Bowtell, David D.L. , Fereday, Sián , Hanley, Gillian E. , Fortner, Renée T , Gentry‐Maharaj, Aleksandra , Harris, Holly R , Matsuo, Keitaro , Menon, Usha , Modugno, Francesmary , Qin, Bo , Ramus, Susan J , Trabert, B , Vierkant, Robert A , Winham, Stacey J , Ziogas, Argyrios , Khoja, Lilah , Cho, Kathleen R , McLean, Karen , Richardson, Jean , Odunsi, Kunle , Nelson, Brad H , Brenton, James D , Webb, Penelope M , Pike, Malcolm C , Fazio, Anna de , Doherty, Jennifer A , Moysich, Kirsten , Bowtell, David D , Fereday, Sian , Goodman, Marc T , Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Cramer, Daniel W., Goode, Ellen L., Goodman, Marc T., Moysich, Kirsten B. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Wentzensen, Nicolas, Wu, Anna H., Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Pharoah, Paul D.P., Berchuck, Andrew, Pearce, Celeste Leigh

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 17, 2021 | Volume: 31 | Issue: 2 | Pages: 443-452

10.1158/1055-9965.epi-21-0977 | PMID 34789471 Get It

Abstract Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. Methods: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. Results: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11–1.54). Conclusions: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. Impact: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease
Ghosh, Auyon , Hobbs, Brian D. , Moll, M, Saferali, Aabida , Boueiz, Adel , Yun, Jeong H. , Sciurba, Frank, Barwick, Lucas, Flaherty, Kevin, Criner, G J, Brown, Kevin K. , Martinez, Fernando J., Lomas, D M, DeMeo, DL, Silverman, E K, Sciurba, Frank C. , Hoffman, Eric A. , Comellas, Alejandro P. , Lomas, David A. , Rossiter, Harry B. , Ghosh, Auyon J , Wise, Robert , Cho, Michael H , Hersh, Craig P , Yun, Jeong H , Hoffman, Eric A , Comellas, Alejandro P , Hobbs, Brian D , Boueiz, Adel , Limper, Andrew H. , Criner, Gerard J. , Wise, Robert A. , Castaldi, Peter J. , Carey, Vincent J. , Cho, Michael H. , Hersh, Craig P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 11, 2021 | Volume: 205 | Issue: 3 | Pages: 313-323

10.1164/rccm.202106-1404oc | PMID 34762809 Get It

Abstract Rationale Multiple studies have demonstrated an increased risk of chronic obstructive pulmonary disease (COPD) in heterozygous carriers of the AAT (alpha-1 antitrypsin) Z allele. However, it is not known if MZ subjects with COPD are phenotypically different from noncarriers (MM genotype) with COPD. Objectives To assess if MZ subjects with COPD have different clinical features compared with MM subjects with COPD. Methods Genotypes of SERPINA1were ascertained by using whole-genome sequencing data in three independent studies. We compared outcomes between MM subjects with COPD and MZ subjects with COPD in each study and combined the results in a meta-analysis. We performed longitudinal and survival analyses to compare outcomes in MM and MZ subjects with COPD over time. Measurements and Main Results We included 290 MZ subjects with COPD and 6,184 MM subjects with COPD across the three studies. MZ subjects had a lower FEV1% predicted and greater quantitative emphysema on chest computed tomography scans compared with MM subjects. In a meta-analysis, the FEV1was 3.9% lower (95% confidence interval [CI], −6.55% to −1.26%) and emphysema (the percentage of lung attenuation areas <−950 HU) was 4.14% greater (95% CI, 1.44% to 6.84%) in MZ subjects. We found one gene, PGF(placental growth factor), to be differentially expressed in lung tissue from one study between MZ subjects and MM subjects. Conclusions Carriers of the AAT Z allele (those who were MZ heterozygous) with COPD had lower lung function and more emphysema than MM subjects with COPD. Taken with the subtle differences in gene expression between the two groups, our findings suggest that MZ subjects represent an endotype of COPD.
S149 Body Mass Index Changes After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Sehgal, Kanika , Cho, Janice , Saffouri, George, Dierkhising, Ross , Battaglioli, Eric , Kashyap, Purna , Pardi, Darrell S. , Khanna, Sahil

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S65-S65

10.14309/01.ajg.0000773068.26704.ab Get It

BRCA1-BARD1 regulates transcription through modulating topoisomerase IIβ
Bunch, Heeyoun , Jeong, Jaehyeon , Kang, Keunsoo , Jo, Doo Sin , Cong, Anh , Kim, Deukyeong, Chen, Benjamin P.C. , Schellenberg, Matthew J. , Calderwood, Stuart K. , Cong, Anh T Q, Calderwood, Stuart K , Cong, Anh T Q , Kim, Donguk , Cho, Dong‐Hyung , Lee, You Mie

Mayo Clinic

Open Biology | October 6, 2021 | Volume: 11 | Issue: 10 | Pages: No page available

10.1098/rsob.210221 | PMID 34610268 Get It

RNA polymerase II (Pol II)-dependent transcription in stimulus-inducible genes requires topoisomerase IIβ (TOP2B)-mediated DNA strand break and the activation of DNA damage response signalling in humans. Here, we report a novel function of the breast cancer 1 (BRCA1)-BRCA1-associated ring domain 1 (BARD1) complex in this process. We found that BRCA1 is phosphorylated at S1524 by the kinases ataxia-telangiectasia mutated and ATR during gene activation, and that this event is important for productive transcription. Our biochemical and genomic analyses showed that the BRCA1-BARD1 complex interacts with TOP2B in the EGR1 transcription start site and in a large number of protein-coding genes. Intriguingly, the BRCA1-BARD1 complex ubiquitinates TOP2B, which stabilizes TOP2B binding to DNA while BRCA1 phosphorylation at S1524 controls the TOP2B ubiquitination by the complex. Together, these findings suggest the novel function of the BRCA1-BARD1 complex in the regulation of TOP2B and Pol II-mediated gene expression.
Cardiac Surgery in Women in the Current Era: What Are the Gaps in Care?
Cho, Leslie , Kibbe, Melina R. , Bakaeen, Faisal G. , Aggarwal, Niti R., Davis, Melinda B. , Karmalou, Tara, Lawton, Jennifer S. , Ouzounian, Maral , Preventza, Ourania , Russo, Andrea M. , Zwischenberger, Brittany A. , Shroyer, Annie-Laurie W , Shroyer, A. Laurie , Lindley, Kathryn J

Mayo Clinic

Circulation | October 4, 2021 | Volume: 144 | Issue: 14 | Pages: 1172-1185

10.1161/circulationaha.121.056025 | PMID 34606298 Get It

Cardiovascular disease remains the leading cause of morbidity and mortality for women in United States and worldwide. One in 3 women dies from cardiovascular disease, and 45% of women >20 years old have some form of CVD. Historically, women have had higher morbidity and mortality after cardiac surgery. Sex influences pathogenesis, pathophysiology, presentation, postoperative complications, surgical outcomes, and survival. This review summarizes current cardiovascular surgery outcomes as they pertain to women. Specifically, this article seeks to address whether sex disparities in research, surgical referral, and outcomes still exist and to provide strategies to close these gaps. In addition, with the growing population of women of reproductive age with cardiovascular disease and cardiovascular risk factors, indications for cardiac surgery arise in pregnant women. The current review will also address the unique issues associated with this special population.
Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea
Kim, Byung‐Kun , Cho, Soo‐Jin , Kim, Changsoo , Sakai, Fumihiko , Dodick, David W. , Chu, Min Kyung , Kim, Chang Soo , Dodick, David W , Chu, Min Kyung

Mayo Clinic

Journal of Clinical Neurology | September 28, 2021 | Volume: 17 | Issue: 4 | Pages: 546

10.3988/jcn.2021.17.4.546 | PMID 34595863 Get It

Vulvar Crohn's Disease: Clinical Features and Outcomes
Cho, Janice , Loftus, Edward V. , Bruining, David H. , Chedid, Victor , Faubion, William A. , Johnson, Amanda M. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Picco, Michael F., Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Cho, Janice M, Chedid, Victor G , Loftus, Edward V , Farraye, Francis A. , Kisiel, John B. , Malik, Talha A. , Coelho–Prabhu, Nayantara

Mayo Clinic

American Journal of Gastroenterology | September 9, 2021 | Volume: 116 | Issue: 11 | Pages: 2296-2299

10.14309/ajg.0000000000001502 | PMID 34732676 Get It

INTRODUCTION: Vulvar involvement is a rare complication of Crohn's disease (CD). The optimal treatment of vulvar CD is unknown. METHODS: We conducted a 25-year retrospective cohort study of vulvar CD from 3 referral centers. Clinical features and outcomes were studied. RESULTS: Fifty patients were identified. The most common vulvar symptoms were pain (74%), edema (60%), ulcerations (46%), nodules (36%), and abscess (34%). Medical management leading to symptomatic improvement varied, and 5 patients ultimately required surgery. DISCUSSION: Vulvar CD manifests with a broad spectrum of symptoms. Aggressive medical management was frequently effective, although surgery was required in 10% of cases.
Coronary Microcirculatory Dysfunction and Acute Cellular Rejection After Heart Transplantation
Lee, Joo Myung , Choi, Ki Hong, Choi, Jin‐Oh , Shin, Doosup , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Gwon, Hyeon-Cheol , Oh, Jae K., Jeon, Eun-Seok, Song, Young Bin , Hahn, Joo‐Yong , Choi, Seung-Hyuk , Gwon, Hyeon-Cheol , Shin, Doosup , Lee, Joo Myung , Choi, Ki Hong, Choi, Jin-Oh , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Oh, Jae K., Jeon, Eun-Seok

Mayo Clinic

Circulation | September 3, 2021 | Volume: 144 | Issue: 18 | Pages: 1459-1472

10.1161/circulationaha.121.056158 | PMID 34474597 Get It

Background: Acute cellular rejection is a major determinant of mortality and retransplantation after heart transplantation. We sought to evaluate the prognostic implications of coronary microcirculatory dysfunction assessed by index of microcirculatory resistance (IMR) for the risk of acute cellular rejection after heart transplantation. Methods: The present study prospectively enrolled 154 heart transplant recipients who underwent scheduled coronary angiography and invasive coronary physiological assessment 1 month after transplantation. IMR is microcirculatory resistance under maximal hyperemia. By measuring hyperemic mean transit time using 3 injections (4 mL each) of room-temperature saline under maximal hyperemia, IMR was calculated as hyperemic distal coronary pressure×hyperemic mean transit time. The primary end point was biopsy-proven acute cellular rejection of grade ≥2R during 2 years of follow-up after transplantation and was compared by using multivariable Cox proportional hazards regression according to IMR. The incremental prognostic value of IMR, in addition to the model with clinical factors, was evaluated by comparison of C-index, net reclassification index, and integrated discrimination index. Results: The mean age of recipients was 51.2±13.1 years (81.2% male), and the cumulative incidence of acute cellular rejection was 19.0% at 2 years. Patients with acute cellular rejection had significantly higher IMR values at 1 month than those without acute cellular rejection (23.1±8.6 versus 16.8±11.1, P =0.002). IMR was significantly associated with the risk of acute cellular rejection (per 5-U increase: adjusted hazard ratio, 1.18 [95% CI, 1.04–1.34], P =0.011) and the optimal cutoff value of IMR to predict acute cellular rejection was 15. Patients with IMR≥15 showed significantly higher risk of acute cellular rejection than those with IMR<15 (34.4% versus 3.8%; adjusted hazard ratio, 15.3 [95% CI 3.6–65.7], P <0.001). Addition of IMR to clinical variables showed significantly higher discriminant and reclassification ability for risk of acute cellular rejection (C-index 0.87 versus 0.74, P <0.001; net reclassification index 1.05, P <0.001; integrated discrimination index 0.20, P <0.001). Conclusions: Coronary microcirculatory dysfunction assessed by IMR measured early after heart transplantation showed significant association with the risk of acute cellular rejection. In addition to surveillance endomyocardial biopsy, early stratification using IMR could be a clinically useful tool to identify patients at higher risk of future acute cellular rejection after heart transplantation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02798731.
Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
Burry, Lisa , Turner, Justin P. , Tannenbaum, Cara , Cho, Hyung J. , Gathecha, Evelyn , Kisuule, Flora, Vijenthira, Abi , Turner, Justin , Morgenthaler, Timothy, Morgenthaler, Timothy I. , Soong, Christine

Mayo Clinic

Annals of Pharmacotherapy | July 24, 2021 | Volume: 56 | Issue: 4 | Pages: 463-474

10.1177/10600280211033022 | PMID 34301151 Get It

Objective: To describe interventions that target patient, provider, and system barriers to sedative-hypnotic (SH) deprescribing in the community and suggest strategies for healthcare teams. Data Sources: Ovid MEDLINE ALL and EMBASE Classic + EMBASE (March 10, 2021). Study Selection and Data Extraction: English-language studies in primary care settings. Data Synthesis: 20 studies were themed as patient-related and prescriber inertia, physician skills and awareness, and health system constraints. Patient education strategies reduced SH dose for 10% to 62% of participants, leading to discontinuation in 13% to 80% of participants. Policy interventions reduced targeted medication use by 10% to 50%. Relevance to Patient Care and Clinical Practice: Patient engagement and empowerment successfully convince patients to deprescribe chronic SHs. Quality improvement strategies should also consider interventions directed at prescribers, including education and training, drug utilization reviews, or computer alerts indicating a potentially inappropriate prescription by medication, age, dose, or disease. Educational interventions were effective when they facilitated patient engagement and provided information on the harms and limited evidence supporting chronic use as well as the effectiveness of alternatives. Decision support tools were less effective than prescriber education with patient engagement, although they can be readily incorporated in the workflow through prescribing software. Conclusions: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C. , Burton, Leeann B , Chwalisz, Bart K. , Hillis, James , Schaller, Teilo , Amato, Anthony A., Warner, Allison Betof , Cho, Tracey , Clardy, Stacey , Dietrich, Jörg , Dougan, Michael , Doughty, Christopher , Dubey, Divyanshu , Guptill, Jeffrey T. , Johnson, Douglas B. , Juel, Vern C. , Kadish, Robert , Kolb, Noah , LeBoeuf, Nicole R. , Linnoila, Jenny, Mammen, Andrew L. , Martinez‐Lage, Maria , Mooradian, Meghan J. , Naidoo, Jarushka , Neilan, Tomas G. , Reardon, David A. , Rubin, Krista M., Santomasso, Bianca , Sullivan, Ryan J. , Woodman, Karin , Zubiri, Leyre , Louv, William C, Reynolds, Kerry L. , Amato, Anthony A. , Betof Warner, Allison , Dougan, Michael , Mooradian, Meghan J , Naidoo, Jarushka , Sullivan, Ryan J , Zubiri, Leyre , Kolb, Noah A , Clardy, Stacey L , Dubey, Divyanshu , Martinez-Lage, Maria , Cho, Tracey A , Brastianos, Priscilla K. , Cohen, Justine Vanessa , Gelfand, Jeffrey M. , Wang, Nancy

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 19, 2021 | Volume: 9 | Issue: 7 | Pages: e002890

10.1136/jitc-2021-002890 | PMID 34281989 Get It

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.